DDrare: Database of Drug Development for Rare Diseases

告示番号	疾患名（ページ内リンク）	臨床試験数
271	強直性脊椎炎	1

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT00265083 (ClinicalTrials.gov)	December 2005	12/12/2005	A Study of the Safety and Efficacy of Golimumab in Subjects With Active Ankylosing Spondylitis	A Multicenter, Randomized, Double-blind, Placebo-controlled Trial of Golimumab, a Fully Human Anti-TNFalpha MonoclonalAntibody, Administered Subcutaneously, in Subjects With Active Ankylosing Spondylitis	Spondylitis, Ankylosing	Biological: golimumab;Biological: Golimumab (CNTO 148); placebo	Centocor, Inc.	Schering-Plough	Completed	18 Years	N/A	All	356	Phase 3	United States;Belgium;Canada;Finland;France;Germany;Korea, Republic of;Netherlands;Taiwan;United Kingdom

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

NCT00265083
(ClinicalTrials.gov)

December 2005

12/12/2005

A Study of the Safety and Efficacy of Golimumab in Subjects With Active Ankylosing Spondylitis

A Multicenter, Randomized, Double-blind, Placebo-controlled Trial of Golimumab, a Fully Human Anti-TNFalpha MonoclonalAntibody, Administered Subcutaneously, in Subjects With Active Ankylosing Spondylitis

Spondylitis, Ankylosing

Biological: golimumab;Biological: Golimumab (CNTO 148); placebo

Centocor, Inc.

Schering-Plough

Completed

18 Years

N/A

All

356

Phase 3

United States;Belgium;Canada;Finland;France;Germany;Korea, Republic of;Netherlands;Taiwan;United Kingdom